Angiodynamics (ANGO) Change in Accured Expenses (2010 - 2026)

Angiodynamics (ANGO) has 17 years of Change in Accured Expenses data on file, last reported at -$6.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 45.17% year-over-year to -$6.0 million; the trailing twelve-month figure through Feb 2026 stood at -$10.9 million (down 42.43% YoY), and the FY2025 full-year result was -$15.9 million, down 157.67% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$6.0 million, down from $3.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $17.7 million in Q1 2024 and bottomed at -$16.5 million in Q3 2023.
• The 5-year median for Change in Accured Expenses is $2.6 million (2025), against an average of $511176.5.
• The widest annual swing landed in 2022, when Change in Accured Expenses sank 446.88%; it then soared 515.14% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $6.1 million in 2022, then soared by 153.34% to $15.6 million in 2023, then plunged by 51.97% to $7.5 million in 2024, then slumped by 57.48% to $3.2 million in 2025, then tumbled by 289.06% to -$6.0 million in 2026.
• The last three Change in Accured Expenses figures came in at -$6.0 million (Q1 2026), $3.2 million (Q4 2025), and -$10.7 million (Q3 2025), per Business Quant data.

Peer Comparison